Virid­i­an’s $150M of­fer­ing; Sur­rozen scraps IBD drug can­di­date; As­sem­bly ends deal with In­di­ana Uni­ver­si­ty

Plus, news about Vor Bio, Vaxxin­i­ty, Im­mat­ics and Cer­tis On­col­o­gy:

Virid­i­an Ther­a­peu­tics’ $150M pub­lic of­fer­ing: The Waltham, MA-based biotech is sell­ing about 7.1 mil­lion shares of its com­mon stock at $21.00 per share, ex­pect­ing to bring in $150 mil­lion to help ad­vance its clin­i­cal pro­grams. Its stock $VRDN was down about 6% in trad­ing on Thurs­day morn­ing. Back in Oc­to­ber, the com­pa­ny an­nounced a $185 mil­lion pri­vate place­ment when it ap­point­ed for­mer Ma­gen­ta Ther­a­peu­tics ex­ec Stephen Ma­honey as its new CEO. — Kather­ine Lewin

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER